SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
SS-31 is one of the most discussed peptides in the research community, with reports focusing on its effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
What Do Researchers Report About SS-31?
SS-31 (Elamipretide (SS-31)) is one of the most discussed Mitochondrial-targeting tetrapeptide compounds in the peptide research community. Reports span effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
What Are the Most Common Positive Reports?
Researchers frequently cite SS-31's effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction as the primary benefits observed during standard cycles of 12-48 weeks in clinical trials.
The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself. This distinctive profile is a key reason SS-31 maintains its popularity despite the growing number of alternatives.
What Are the Common Criticisms?
The most common complaints about SS-31: Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Cost and sourcing quality are also frequent concerns — results vary significantly between vendors, which is why COA testing is essential.
How Does SS-31 Compare to Alternatives?
As a Mitochondrial-targeting tetrapeptide, SS-31 competes with several similar compounds. The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself.
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
Bottom Line: Is SS-31 Worth It?
Based on the available research and community reports, SS-31 is well-regarded for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. The key factors for success: consistent dosing (4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV daily subcutaneous or weekly IV infusion), quality sourcing, and realistic expectations over 12-48 weeks in clinical trials cycles.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.